Published in Support Care Cancer on April 21, 2013
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer (2014) 1.93
Oral complications in hematopoietic stem cell recipients: the role of inflammation. Mediators Inflamm (2014) 0.84
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks. Int J Mol Sci (2014) 0.81
Double-blind, randomized pilot study of bioadhesive chlorhexidine gel in the prevention and treatment of mucositis induced by chemoradiotherapy of head and neck cancer. Med Oral Patol Oral Cir Bucal (2015) 0.80
Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. Nutrients (2013) 0.79
Combined Effects of Muricid Extract and 5-Fluorouracil on Intestinal Toxicity in Rats. Evid Based Complement Alternat Med (2015) 0.78
Hyposmia: an underestimated and frequent adverse effect of chemotherapy. Support Care Cancer (2015) 0.77
Topical application of Aloe vera and vitamin E on induced ulcers on the tongue of rats subjected to radiation: clinical and histological evaluation. Support Care Cancer (2015) 0.77
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med (2016) 0.75
New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Front Pharmacol (2017) 0.75
Melatonin protects rats from radiotherapy-induced small intestine toxicity. PLoS One (2017) 0.75
Effect of Kangfuxin Solution on Chemo/Radiotherapy-Induced Mucositis in Nasopharyngeal Carcinoma Patients: A Multicenter, Prospective Randomized Phase III Clinical Study. Evid Based Complement Alternat Med (2016) 0.75
Tachykinin peptide, substance P, and its receptor NK-1R play an important role in alimentary tract mucosal inflammation during cytotoxic therapy. Dig Dis Sci (2014) 0.75
Mucositis care in acute leukemia and non-Hodgkin lymphoma patients undergoing high-dose chemotherapy. Support Care Cancer (2014) 0.75
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology (1998) 9.58
Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 7.13
Apoptosis. Its significance in cancer and cancer therapy. Cancer (1994) 6.71
The extracellular matrix as a cell survival factor. Mol Biol Cell (1993) 6.32
Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer (2004) 3.83
Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis (2003) 3.53
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol (2004) 3.12
The pathobiology of mucositis. Nat Rev Cancer (2004) 2.99
Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer (2007) 2.95
Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis (1994) 2.61
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer (2003) 2.46
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol (2002) 2.33
Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol (2008) 1.83
The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog (2010) 1.77
Apoptosis and the dilemma of cancer chemotherapy. Blood (1997) 1.71
Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol (2009) 1.67
Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer (2006) 1.64
Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol (2009) 1.63
Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut (2000) 1.55
Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting. Oncologist (1998) 1.52
Methotrexate modulates tight junctions through NF-κB, MEK, and JNK pathways. J Pediatr Gastroenterol Nutr (2012) 1.51
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol (2007) 1.42
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist (2004) 1.42
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
A biological approach to mucositis. J Support Oncol (2004) 1.29
The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer (1998) 1.29
Proinflammatory cytokines cause NO*-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock (2003) 1.28
Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer (2010) 1.27
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol (2000) 1.22
Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys (2009) 1.22
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol (2008) 1.20
The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med (2002) 1.15
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer (2009) 1.15
An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol (1990) 1.14
Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer (2005) 1.14
The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol (2004) 1.13
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis (2003) 1.10
IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway. Am J Pathol (2010) 1.08
Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant (2000) 1.08
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci (2004) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol (2007) 1.05
Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol (2011) 1.04
Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol (2011) 1.04
Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol (2006) 1.03
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol (2001) 1.02
Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology (2005) 1.00
Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci (2002) 0.99
Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol (2007) 0.98
Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer (2006) 0.96
Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. Biochem Biophys Res Commun (2009) 0.95
Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats. Cancer Chemother Pharmacol (2010) 0.95
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer (2011) 0.94
Bacterial substitution of coagulase-negative staphylococci for streptococci on the oral mucosa after hematopoietic cell transplantation. Support Care Cancer (2010) 0.94
Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab (2009) 0.93
Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer (2008) 0.92
Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92
A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol Blood Marrow Transplant (2010) 0.92
Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer (2008) 0.91
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol (2009) 0.91
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) (2007) 0.89
A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant (2002) 0.89
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. Eur J Oral Sci (2005) 0.88
Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88
Genome-wide association studies and prediction of normal tissue toxicity. Semin Radiat Oncol (2012) 0.87
The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif (2002) 0.87
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol (2008) 0.86
Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) (2010) 0.85
Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy (2007) 0.85
Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol (1992) 0.85
Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 0.84
Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy (2005) 0.84
New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer (2006) 0.83
Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res (2004) 0.83
Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med (2005) 0.83
Role of AMP-18 in oral mucositis. Oral Oncol (2011) 0.83
Effects of intensity-modulated radiotherapy on human oral microflora. J Radiat Res (2011) 0.82
Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet Cytogenet (2010) 0.82
Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori (2004) 0.81
Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther (2011) 0.80
The correlation between the severity of radiotherapy-induced glossitis and endothelial cell injury in local tissues in a rat model. Med Oral Patol Oral Cir Bucal (2011) 0.80
Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs (2008) 0.80
Opportunistic gram-negative bacillary infections in leukemia. Oral manifestations during myelosuppression. Postgrad Med (1974) 0.78
Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther (2012) 0.77
The role of oral microorganisms in cancer therapy. Curr Opin Dent (1992) 0.77
New frontiers in mucositis. Am Soc Clin Oncol Educ Book (2012) 0.77
Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. Int J Exp Pathol (2011) 0.76
Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model. Chemotherapy (2007) 0.75
Lymphocyte subsets, granulocyte-colony-stimulating factor responsiveness and post-stem cell transplantation infections: mucositis is the underestimated confounder? Cytotherapy (2012) 0.75
Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer (2007) 2.95
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer (2004) 2.29
Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24
Animal models of mucositis: implications for therapy. J Support Oncol (2011) 2.13
Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab (2006) 1.98
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer (2014) 1.93
Management of oral mucositis in patients who have cancer. Dent Clin North Am (2008) 1.72
Effect of stressful life events on the onset and duration of recurrent aphthous stomatitis. J Oral Pathol Med (2011) 1.66
Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer (2006) 1.64
Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum (2011) 1.54
Microarrays and clinical dentistry. J Am Dent Assoc (2003) 1.53
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
A survey of the current approaches to diagnosis and management of oral premalignant lesions. J Am Dent Assoc (2007) 1.47
Intraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 1.46
Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent. Haematologica (2005) 1.40
Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment : a retrospective and a prospective study. Support Care Cancer (2012) 1.40
Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU). Cancer Biol Ther (2009) 1.39
Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother (2011) 1.39
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant (2010) 1.33
Management of dental patients taking common hemostasis-altering medications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 1.31
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg (2009) 1.26
Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. Am J Physiol Renal Physiol (2013) 1.25
Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.23
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.17
Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.16
Swallowing dysfunction in cancer patients. Support Care Cancer (2011) 1.12
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Interruption of warfarin anticoagulation for dental surgery. Chest (2013) 1.11
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10
Oral mucositis. Oral Oncol (2010) 1.10
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig (2010) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer (2010) 1.05
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.04
Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis (2003) 1.04
Salen Mn complexes mitigate radiation injury in normal tissues. Anticancer Agents Med Chem (2011) 1.03
Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer (2012) 1.03
Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.02
Reduced dietary intake of vitamin B12 and folate in patients with recurrent aphthous stomatitis. J Oral Pathol Med (2010) 1.01
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer (2009) 1.01
Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00
Gastrointestinal mucositis. Semin Oncol Nurs (2004) 1.00
Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology (2005) 1.00
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.00
Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: update 2011. Support Care Cancer (2011) 0.99
Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol (2013) 0.98
Mucositis: pathobiology and management. Curr Opin Oncol (2015) 0.98
Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res (2008) 0.98
Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis. Radiat Res (2014) 0.98